Articles tagged with Multiple Sclerosis
A subanalysis of the MEMREHAB trial found that deficits in processing speed negatively affect the benefits of the modified Story Memory Technique (mSMT) for individuals with MS. Processing speed may be an indicator of cognitive decline, which can impact the effectiveness of mSMT.
Researchers discovered that increasing brain activity can stimulate myelin production, which protects nerve fibers. This finding could lead to new treatments for multiple sclerosis.
A new trial will evaluate strategies to improve attention and memory for people with multiple sclerosis, aiming to boost everyday life activities. The 10-week group intervention will focus on improving attention and reducing memory problems in daily life.
Researchers have developed a new drug-like molecule called WEHI-345 that binds to and inhibits a key immune signalling protein, preventing the release of inflammatory cytokines. The molecule showed promise in preventing the progression of multiple sclerosis in 50% of cases.
A study found that guanabenz, a blood pressure medication, enhances an innate cellular protective response and prevents myelin loss in animal models of multiple sclerosis. The drug's unique mechanism provides protection against MS by reducing inflammation and preserving myelin levels.
Researchers discovered a genetic variation, STK11 SNP, significantly increasing the risk of developing multiple sclerosis in women. The study involved three sisters among five siblings with MS and found the variant to be prevalent in 7% of the general population.
Researchers found that a protein called TREM2 triggers the clearance of debris from the brain, which can contribute to neurological diseases. Triggering this protein may help slow the progression of conditions like Alzheimer's and multiple sclerosis.
Researchers have discovered a way to keep remyelination going using an FDA-approved drug solifenacin, which boosts myelin synthesis and improves auditory function in mice with myelin-related disease. The study shows that targeting human oligodendrocyte progenitor cells with solifenacin promotes differentiation and myelin production.
A new study by University of Vermont neurologist Andrew Solomon and colleagues reports that MS patients want to know the details of their physicians' financial relationships with pharmaceutical companies. The study found that disclosure of these relationships can influence patients' decisions to participate in clinical trials.
A new study suggests that drinking coffee may reduce the risk of developing multiple sclerosis (MS). Researchers analyzed data from two studies involving over 3,700 people with MS and found that those who consumed high amounts of coffee had a lower risk of developing the disease. The study supports the idea that caffeine may have prote...
Women with multiple sclerosis may have lower levels of important antioxidant and anti-inflammatory nutrients like folate from food and vitamin E compared to healthy people. The study found that women with MS had lower average intake of these nutrients and a lower percentage of calories from fat.
A new treatment shows promise in reducing muscle cramp intensity by three times, taking effect within minutes and lasting up to six hours.
A promising new approach to treat multiple sclerosis has been discovered by scientists at the Centre for Addiction and Mental Health. They identified a previously unknown change in the spinal cord related to MS and developed a peptide that disrupts this change, leading to major improvements in neurological functioning.
Researchers at Trinity College Dublin have identified a breakthrough molecule, MCC950, that suppresses the NLRP3 inflammasome, a key process in inflammatory diseases. The discovery has significant implications for treating various conditions, including arthritis, multiple sclerosis, and Muckle-Wells syndrome.
A new study found that stem cell transplants significantly reduced disease activity and brain damage in people with severe multiple sclerosis, compared to the existing drug mitoxantrone. The treatment showed promise as a potential alternative for those not responding well to standard treatments.
Kessler Foundation researchers found that subjective and objective cognitive fatigue are independent factors, with increased time on task leading to higher levels of fatigue in MS individuals. Task length was the key factor associated with cognitive fatigue, supporting the Temporal Fatigue hypothesis.
A preliminary study found that nonmyeloablative hematopoietic stem cell transplantation improved measures of disability and quality of life in relapsing-remitting multiple sclerosis patients. The treatment also showed significant improvement in physical function, cognitive function, and a reduction in brain lesions associated with MS.
A common gut microbe may protect against multiple sclerosis (MS) in women. The study found that women with MS who tested positive for Helicobacter pylori had lower disability scores than those who tested negative.
A large-scale study in Denmark and Sweden found no increased risk of multiple sclerosis among girls and women who received HPV vaccination. The study analyzed over 3.9 million individuals and 1.9 million vaccine doses, concluding that the qHPV vaccine is safe for use in this population.
After a small number of MS patients received high-dose immunosuppressive therapy and then transplanted with their own hematopoietic stem cells, most sustained remission of active relapsing-remitting MS. Improvements in neurological function, quality-of-life, and functional scores were also noted.
A study of 219 MS patients found that only 46% maintained no-evidence-of-disease-activity for clinical and MRI measures at one year, decreasing to 27.5% at two years and 7.9% after seven years.
Researchers at CWRU developed a 24-week home-based exercise program using customized pamphlets to help people with MS stay physically active. The program showed promise in improving physical function and reducing symptom severity, particularly for women with relapsing-remitting MS.
Carmela Abraham, a professor at Boston University School of Medicine, has received the Massachusetts Neuroscience Consortium Award for her research on multiple sclerosis and the life extension protein Klotho. Her work identifies Klotho as a neuroprotective protein that can benefit animal models of Alzheimer's and multiple sclerosis.
A team of researchers from the University of Surrey has identified a rogue protein in multiple sclerosis, which attacks the body's central nervous system. The discovery could lead to a better understanding of the disease and new treatments against neurodegenerative diseases.
A team of researchers has identified a chemical compound called indazole chloride that can decrease the effects of multiple sclerosis. Ind-Cl works by inhibiting selective inflammation and remyelinating axons, restoring neuronal function and potentially reducing MS progression.
Researchers found a new type of immune T helper cells called TH-GM cells play a crucial role in the immune system and pathogenesis of neuronal inflammation. Blocking IL-7 or STAT5 could provide significant therapeutic benefits for MS.
A new study by Penn and Dresden researchers has identified the protein Del-1 as a key player in blocking multiple sclerosis relapses in mice. The protein, also found to prevent inflammation and bone loss in gum disease, shows promise as a potential therapeutic target for treating neurodegenerative diseases.
A new study demonstrates that people with multiple sclerosis often have trouble recognizing emotions conveyed by facial expressions, and now shows similar difficulties with emotions expressed through body posture. The research suggests that this difficulty is unrelated to identifying one's own emotions, a disorder known as alexithymia.
A new study pinpoints the complex genetic origins of multiple autoimmune diseases, including type 1 diabetes and MS. The researchers discovered that specific DNA variations, even outside genes, can alter immune system functions. Epigenetic characteristics of immune cells were also found to play a crucial role in disease development.
Researchers developed a mathematical model to analyze data from genome-wide association studies, pinpointing genetic variants that cause autoimmune diseases. The study found strong links between the immune system and neurologic disease MS, suggesting a primary role of the immune system in causing the disease.
Researchers at EMBL found that IGF-1 enhances T-reg cell production, suppressing auto-immune diseases like type-1 diabetes and multiple sclerosis. The molecule is already approved for use in patients, paving the way for clinical trials.
The Weizmann Institute of Science has developed a novel, highly active interferon variant called YNSalpha8. PASylation technology extended its half-life in the body, resulting in improved protection from disease progression in a mouse model of human multiple sclerosis.
A recent study published in JAMA Neurology found no long-term link between vaccine administration and the development of multiple sclerosis (MS) or other central nervous system demyelinating syndromes. However, a short-term increased risk was observed in younger patients, which may be attributed to existing disease.
A large retrospective study found that nearly 60% of patients with both uveitis and multiple sclerosis (MS) are diagnosed with each condition within a five-year span. The study also revealed that MS is more likely to be diagnosed before or after uveitis, not simultaneously.
Dr. Lauren Strober will update the Symbol Digit Modalities Test (SDMT) to improve its use in clinical settings for individuals with Multiple Sclerosis (MS). The updated test will more accurately assess processing speed changes over time, enabling better prediction of disease progression and outcomes.
The Oklahoma Medical Research Foundation will receive a two-year $280,000 grant to investigate the role of BAFF and APRIL molecules in multiple sclerosis progression. This project aims to understand how inhibiting these molecules affects disease symptoms in experimental models.
Researchers found that patients with Multiple Sclerosis (MS) can safely tolerate treatment with cells cultured from human placental tissue. Early signals also suggest the potential for repairing damaged nerve tissues, offering a new frontier in treatment for the disease.
A 10-week psychoeducational wellness program improved mood, overall mental health, perceived stress, and pain in people with multiple sclerosis. The study, published in the International Journal of MS Care, suggests that individuals with MS may benefit from comprehensive wellness programs.
The International Progressive Multiple Sclerosis (MS) Alliance awarded a $30 million grant to researchers worldwide to tackle the devastating form of MS. Kessler Foundation's pilot study in rehabilitation addresses cognitive dysfunction, aiming to improve quality of life for individuals with progressive MS.
Kessler Foundation researchers have discovered a link between slowed processing speed and executive deficits in people with multiple sclerosis. The study found that slower processing speed accounted for the observed executive function deficits, suggesting a potential target for cognitive rehabilitation strategies.
A large-scale study found that more than 70% of individuals with multiple sclerosis screened positive for one or more sleep disorders, highlighting the importance of diagnosing and managing these conditions. The study's findings suggest that sleep problems may be a hidden epidemic in the MS population, separate from MS fatigue.
Researchers found that people with multiple sclerosis (MS) lose myelin in their gray matter, a characteristic of the disease that affects brain function. The study's findings suggest that gray matter demyelination is strongly related to MS disability and have important implications for treatment monitoring and clinical trials.
Researchers at Kessler Foundation found that working memory capacity explains the relationship between intellectual enrichment and long-term memory in individuals with MS. This suggests that interventions targeting working memory may help build cognitive reserve to protect against decline in long-term memory.
Researchers at Lund University discovered inflammation and changes in the intestinal barrier function early in MS, indicating a potential link to disease progression. The study suggests that damage to the intestinal barrier may prevent the body from ending an autoimmune reaction, leading to chronic diseases like MS.
Researchers at the University of Bristol have made a breakthrough in understanding how cells convert from attacking healthy tissue to protecting against disease. This discovery could lead to the development of a new treatment approach using antigen-specific immunotherapy, which may improve the lives of millions worldwide.
A study of 70 people with relapsing-remitting multiple sclerosis found that high dietary salt intake was associated with more episodes of worsening symptoms and a higher likelihood of radiological signs of disease progression. Vitamin D levels also played a role, with low levels linked to the disease.
A new treatment, anti-LINGO-1, has been found to be safe and tolerable in phase I clinical trials for multiple sclerosis. The treatment blocks a protein that prevents myelination, potentially repairing damaged nerves.
Researchers used functional near infrared spectroscopy (fNIRS) to examine brain activation during a working memory task in people with multiple sclerosis (MS) and healthy controls. The study found differences in brain activation patterns between the groups that were dependent on task load.
A new study published in Radiology found that using the Wii Balance Board system can induce favorable changes in brain connections associated with balance and movement in patients with multiple sclerosis. The device helps improve balance, reducing the risk of accidental falls and related comorbidities.
A new Kessler Foundation study reveals that people with multiple sclerosis (MS) can enhance their self-awareness through hands-on task experiences. Researchers found improved metacognitive knowledge and online awareness in participants, suggesting potential benefits for cognitive rehabilitation.
A new study identifies a novel gene, Inpp4b, that controls nerve conduction velocity and is linked to multiple sclerosis. The researchers found that polymorphisms in this gene affect nerve conduction speed in both mice with experimental autoimmune encephalomyelitis (EAE) and humans with MS.
Cognitive research by Kessler Foundation scientists reveals that unexpected task constraint following self-generated task choice impairs task-switching performance. The study shows that individuals struggle to undo preparation for a task, leading to negative effects on multitasking ability.
Researchers explore the link between gut microbiome and autoimmune disorders like multiple sclerosis, highlighting potential therapeutic targets. The study suggests that the gut microbiome plays a crucial role in immune cell activity and cytokine production, which may impact susceptibility to and treatment of autoimmune diseases.
Researchers at The New York Stem Cell Foundation have developed a new protocol to induce pluripotent stem cells into oligodendrocytes, the myelin-forming cells implicated in multiple sclerosis. This accelerated approach cuts production time almost in half, enabling researchers to study disease progression and develop potential treatments.
A new study reveals that microglia can increase neuronal firing and enhance brain cell survival after traumatic brain injury, potentially slowing the progression of neurodegenerative diseases. The research found that activated microglia dislodge inhibitory synapses, leading to increased firing and enhanced survival.
Researchers at the University at Buffalo have identified SOX10 as a key transcription factor that initiates myelination in human brain cells. This discovery brings researchers closer to developing a viral or pharmaceutical approach to inducing SOX10 in MS patients, which could lead to a more effective treatment for multiple sclerosis.
A longitudinal study of 22 MS patients found significant declines in cognitive function, including processing speed and memory, over an 18-year period. The study provides valuable insights into the natural evolution of cognitive changes in MS.
Human embryonic stem cell therapy has been shown to significantly reduce MS disease severity in animal models, offering a promising new treatment for the debilitating disease. The therapy also provides an unlimited source of high-quality mesenchymal stem cells, which can be propagated indefinitely in lab cultures.
A new report refines descriptions of multiple sclerosis (MS) courses, categorizing progressive relapsing as an active form of primary progressive MS. The updated definitions aim to enhance research, clinician-patient communication, and clinical trial design.
Researchers enrolled 120 MS patients and 60 healthy controls, finding no significant difference in diagnosed chronic cerebrospinal venous insufficiency between groups. The study's findings dispute the theory linking CSVI to MS due to methodological concerns and questionable diagnosis criteria.